Royalty Pharma PLC

CEO Legorreta’s bulk buy of Royalty Pharma shares signals strong confidence in the company’s royalty‑acquisition growth strategy and upcoming deals.

Explore how Royalty Pharma’s CFO Coyne’s latest 10‑b‑5‑1 insider sale may signal future earnings momentum or market caution, and what it means for investors.

Royalty Pharma insiders sell shares at flat prices amid new Teva deal – understand the structured sales, valuation, and long‑term royalty upside for investors.